平衡个体炎症性肠病患者免疫抑制治疗的获益与风险
炎症性肠病(IBD)及其治疗尤其是免疫抑制药物增加感染和癌症风险,但通过促进黏膜愈合可能降低感染和癌症风险;不同药物类别及患者性别年龄的风险各异,需基于年龄、性别和IBD表型调整获益风险模型以指导管理。
要点
- 免疫抑制药物增加感染和癌症风险,但促进黏膜愈合可能降低相关风险。
- 感染和癌症风险的性质与程度随药物类别及患者性别、年龄而异。
- 决策应首先清晰解释治疗风险,再整合患者对风险的情感感知。
核心结论
- 评估IBD患者长期使用免疫抑制药物的获益风险比模型应基于年龄、性别和IBD表型调整,以正确指导患者管理。
研究设计与样本
- 原文为综述,未报告系统检索范围。
主要发现
- 免疫抑制药物增加感染和癌症风险,但促进黏膜愈合可能降低与肠道病变、营养不良、静脉装置和IBD手术相关的感染风险及慢性黏膜炎症相关癌症风险,支持此概念的数据很少。
- 糖皮质激素增加血管血栓栓塞事件风险,而诱导IBD深度缓解的其他免疫抑制药物可能降低全身炎症和IBD相关住院和/或手术所致心血管事件发生率。
- 硫嘌呤增加病毒感染风险,年轻患者可能致命;肿瘤坏死因子拮抗剂增加细菌和细胞内感染风险,任何年龄均可能致命,老年患者尤其。
- 药物预防IBD相关结直肠癌的能力随IBD部位和病程而异。
临床怎么用
- 决策过程应首先清晰解释治疗风险,然后整合患者对风险的情感感知。
- 评估长期免疫抑制治疗获益风险比的模型应基于患者年龄、性别和IBD表型调整。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammatory bowel diseases (IBD) and their treatments, particularly immunosuppressive drugs, increase risk of infections and cancers. However, by promoting mucosal healing, these agents should reduce risks of infections related to intestinal lesions, malnutrition, intravenous devices, and IBD surgeries and reduce risk of cancers associated with chronic mucosal inflammation-although there are few data to support this concept. Corticosteroids increase the risk of vascular thromboembolic events, yet other immunosuppressive drugs that induce deep remission from IBD could decrease the incidence of cardiovascular events attributable to systemic inflammation and IBD-related hospitalizations and/or surgeries. The nature and magnitude of the risks of infections and cancers vary with immunosuppressive drug class and patient sex and age. For example, thiopurines increase risk of viral infections that might be fatal in young patients, whereas tumor necrosis factor antagonists increase risk of bacterial and intracellular infections that can be fatal in patients of any age, but particularly in older patients. The ability of drugs to prevent IBD-associated colorectal cancer varies with IBD location and duration. Models to assess the benefit:risk ratio of long-term use of immunosuppressive drugs for patients with IBD should be adapted based on patients' age, sex, and IBD phenotype, to properly guide patient management. The decision-making process should begin with a clear explanation of treatment risks and then integrate the patient's emotional perception of risks.
引用
- Beaugerie L, Kirchgesner J. Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018. PMID: 30031174. doi:10.1016/j.cgh.2018.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。